Login to Your Account



Visionary Eyetech Saw Aptamers' Value, Turned Macugen Into Gold

By Randall Osborne


Monday, April 26, 2004

Eyetech Pharmaceuticals Inc.'s CEO David Guyer typically is humble when he talks about the company's landmark potential $750 million deal in late 2002 with Pfizer Inc. for Macugen, the in-licensed aptamer for age-related macular degeneration.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription